Grace Therapeutics (NASDAQ: GRCE) announced its participation in the BIO 2025 International Conference, taking place in Boston from June 16-19, 2025. CEO Prashant Kohli will represent the company at this major biotechnology event, which attracts over 20,000 global leaders from biopharma, academia, investment, and government sectors. Grace Therapeutics is developing GTx-104, a novel injectable formulation of nimodipine for IV infusion, targeting unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients. Interested parties can schedule meetings with Mr. Kohli through the BIO Partnering platform or by contacting the company directly.
Grace Therapeutics (NASDAQ: GRCE) ha annunciato la sua partecipazione alla conferenza internazionale BIO 2025, che si terrà a Boston dal 16 al 19 giugno 2025. Il CEO Prashant Kohli rappresenterà l'azienda in questo importante evento biotecnologico, che riunisce oltre 20.000 leader mondiali provenienti dai settori biofarmaceutico, accademico, degli investimenti e governativo. Grace Therapeutics sta sviluppando GTx-104, una nuova formulazione iniettabile di nimodipina per infusione endovenosa, rivolta a soddisfare bisogni medici insoddisfatti nei pazienti con emorragia subaracnoidea aneurismatica (aSAH). Gli interessati possono fissare un incontro con il Sig. Kohli tramite la piattaforma BIO Partnering o contattando direttamente l'azienda.
Grace Therapeutics (NASDAQ: GRCE) anunció su participación en la Conferencia Internacional BIO 2025, que se llevará a cabo en Boston del 16 al 19 de junio de 2025. El CEO Prashant Kohli representará a la compañía en este importante evento biotecnológico, que reúne a más de 20,000 líderes globales de los sectores biofarmacéutico, académico, de inversión y gubernamental. Grace Therapeutics está desarrollando GTx-104, una nueva formulación inyectable de nimodipina para infusión intravenosa, dirigida a cubrir necesidades médicas no satisfechas en pacientes con hemorragia subaracnoidea aneurismática (aSAH). Los interesados pueden programar reuniones con el Sr. Kohli a través de la plataforma BIO Partnering o contactando directamente a la empresa.
Grace Therapeutics(NASDAQ: GRCE)는 2025년 6월 16일부터 19일까지 보스턴에서 열리는 BIO 2025 국제 컨퍼런스에 참가한다고 발표했습니다. CEO 프라샨트 콜리(Prashant Kohli)가 이 주요 바이오테크 행사에서 회사를 대표할 예정이며, 이 행사는 바이오제약, 학계, 투자 및 정부 부문의 20,000명 이상의 글로벌 리더들이 참여합니다. Grace Therapeutics는 동맥류성 지주막하출혈(aSAH) 환자의 미충족 의료 수요를 겨냥한 새로운 주사제 형태의 니모디핀 정맥주사제 GTx-104를 개발 중입니다. 관심 있는 분들은 BIO 파트너링 플랫폼을 통해 또는 회사에 직접 연락하여 콜리 대표와 미팅을 예약할 수 있습니다.
Grace Therapeutics (NASDAQ : GRCE) a annoncé sa participation à la conférence internationale BIO 2025, qui se tiendra à Boston du 16 au 19 juin 2025. Le PDG Prashant Kohli représentera la société lors de cet événement majeur en biotechnologie, qui rassemble plus de 20 000 leaders mondiaux issus des secteurs biopharmaceutique, académique, de l'investissement et gouvernemental. Grace Therapeutics développe le GTx-104, une nouvelle formulation injectable de nimodipine pour perfusion intraveineuse, visant à répondre aux besoins médicaux non satisfaits des patients souffrant d'hémorragie sous-arachnoïdienne anévrismale (aSAH). Les personnes intéressées peuvent prendre rendez-vous avec M. Kohli via la plateforme BIO Partnering ou en contactant directement la société.
Grace Therapeutics (NASDAQ: GRCE) gab seine Teilnahme an der BIO 2025 International Conference bekannt, die vom 16. bis 19. Juni 2025 in Boston stattfindet. CEO Prashant Kohli wird das Unternehmen auf dieser bedeutenden Biotechnologie-Veranstaltung vertreten, die über 20.000 globale Führungskräfte aus den Bereichen Biopharma, Wissenschaft, Investment und Regierung anzieht. Grace Therapeutics entwickelt GTx-104, eine neuartige injizierbare Formulierung von Nimodipin für die intravenöse Infusion, die auf ungedeckte medizinische Bedürfnisse bei Patienten mit aneurysmatischer Subarachnoidalblutung (aSAH) abzielt. Interessierte können Termine mit Herrn Kohli über die BIO Partnering-Plattform oder direkt beim Unternehmen vereinbaren.
Positive
None.
Negative
None.
PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate in the upcoming BIO 2025 International Conference, to be held in Boston, MA, June 16-19, 2025.
Hosted by the Biotechnology Innovation Organization (BIO), the BIO International Convention is the world’s largest and most influential biotechnology event, convening more than 20,000 global leaders from across the life sciences ecosystem, including biopharma, academia, investment, and government. The convention provides companies with unique access to a partnering forum.
aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain. The result is a relatively uncommon type of stroke (aSAH) that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital treated patients.
About GTx-104
GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion.
GTx-104 provides a convenient IV delivery of nimodipine in the Intensive Care Unit potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTx-104 has the potential to better manage hypotension in aSAH patients. GTx-104 has been administered in over 150 healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to oral nimodipine.
About Grace Therapeutics
Grace Therapeutics, Inc. (formerly Acasti, Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutic’s lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Grace Therapeutics’ lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull.
LifeSci Advisors Mike Moyer Managing Director Phone: 617-308-4306 Email: mmoyer@lifesciadvisors.com
FAQ
When and where is Grace Therapeutics (GRCE) participating in the BIO International Conference 2025?
Grace Therapeutics will participate in the BIO International Conference from June 16-19, 2025, in Boston, MA.
What is Grace Therapeutics' (GRCE) main product in development?
Grace Therapeutics is developing GTx-104, a novel injectable formulation of nimodipine for IV infusion, targeting aneurysmal subarachnoid hemorrhage (aSAH) patients.
Who will represent Grace Therapeutics (GRCE) at the BIO 2025 Conference?
Chief Executive Officer Prashant Kohli will represent Grace Therapeutics at the BIO 2025 International Conference.
How can investors meet with Grace Therapeutics' (GRCE) management at the BIO Conference?
Meetings can be requested through the BIO Partnering platform at convention.bio.org/registration or by emailing info@gracetx.com.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
